Origins
When was tesamorelin created?
Tesamorelin is the growth-hormone-axis peptide in this range that actually reached approval, in the United States in 2010.
The short answer
| Date | Approved 2010 |
| Who | Theratechnologies |
| Where | Montreal, Canada |
| Origin | Designed, not found — it does not occur naturally in this form. |
Where it came from
The design takes the full forty-four-residue growth-hormone-releasing hormone rather than the shortened GHRH(1-29) that sermorelin and CJC-1295 are built on, and attaches a trans-3-hexenoyl group to the N-terminus. That group blocks the enzyme dipeptidyl peptidase-4 from making its usual cut at the start of the chain — the same vulnerability, solved a different way from how ConjuChem solved it.
Comparing the two is the useful thing here. CJC-1295 buys time by hitching a ride on albumin; tesamorelin buys time by putting a chemical obstruction where the enzyme needs to bind. Both are answers to one problem, and only one of them was carried all the way through trials.
The 2010 date is the FDA approval, which is the firmest date available. The development work runs back through the 2000s.
Why it is called that
The -relin ending again, marking the growth-hormone-releasing axis. Tesamorelin is an international nonproprietary name; the approved product is Egrifta.
Where it stands now
Tesamorelin is approved in the United States for a specific indication. It is not approved in New Zealand, and material supplied for laboratory work is not the approved product.
What this page does not say
Nothing above is a statement about what Tesamorelin does in a body, and none of it is guidance on use. A compound’s history is a record of laboratories and dates; it is not evidence for anything, and the fact that a programme was looking for something is not a finding that it was found.
More on Tesamorelin
What is Tesamorelin? · The full timeline · Tesamorelin — sizes and prices
